Company news

Orthocell Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Remplir Approved to Commence Sales in US$75m Canadian Market

April 29, 2025

Replacement Trading Halt

April 29, 2025

Pause in Trading

April 29, 2025

Remplir Approved to Commence Sales in US$84M Thai Market

April 27, 2025

First US Distributors Signed for Remplirs US$1.6B market

April 23, 2025

Regulatory Approval for Striate in US$65M Brazilian Market

April 8, 2025

Remplir Cleared to Commence Sales in US$1.6B US Market

April 3, 2025

Investor Presentation - US FDA 510(k) Clearance for Remplir

April 3, 2025

First Sales of Striate in Germany, Austria & Swiss Region

March 25, 2025

Regulatory approval to commence Striate sales in Singapore

March 17, 2025

S&P DJI Announces March 2025 Quarterly Rebalance

March 7, 2025

Orthocell Receives $3.18 million R&D Tax Refund

January 19, 2025

Third Consecutive Quarter of Record Revenue for Orthocell

January 7, 2025

US FDA Application Submitted for Remplir as US Launch Nears

December 18, 2024

Major Milestone with First Sales of Remplir in Singapore

December 11, 2024

Outstanding Remplir Study Results Pave Way for FDA Clearance

December 1, 2024

Distributor Signed, Remplir Sales in Singapore to Commence

November 26, 2024

Key Executives Appointed to Drive Remplir US Sales

November 10, 2024

Orthocell completes $17m Placement

October 30, 2024

$17m Placement to Drive Further Growth as US Approval Nears

October 24, 2024

Regulatory approval to commence Remplir sales in Singapore

October 7, 2024

Second Consecutive Record Quarter as Revenue Exceeds $2m

October 6, 2024

First sales of Striate in major new market of Canada

September 5, 2024

Company Presentation

August 29, 2024

Regulatory Approval to Commence Sales for Striate in Canada

July 10, 2024

Record Quarterly and Yearly Revenue Show Outstanding Growth

July 8, 2024

Third Revenue Generating Product to be Launched in SmrtGraft

June 10, 2024

Orthocell reports 98.6% success rate in Striate+â„¢ dental membrane study

May 15, 2024

Outstanding 98.6% Success Rate in Striate Implant Study

May 13, 2024

Orthocell receives $3.05m R&D tax incentive refund

April 14, 2024

Part 1 Remplir US Market Authorisation Successfully Complete

March 24, 2024

Appendix 4D & Half-Year Financial Statements

February 23, 2024

Strategic Placement to Raise $3.5 million

February 21, 2024

Remplir Expansion Continues with Singapore Application

February 12, 2024

Successful OrthoATI clinical trial

November 13, 2023

UWA Royalty Entitlement Exchanged for Shares in Orthocell

October 29, 2023

Striate re-certified under new European medical device regs

August 23, 2023

Orthocell receives A$3.17m R&D tax incentive refund

June 20, 2023

Orthocell commences nerve repair study

April 17, 2023

Leading US-based nerve surgeons appointed to advisory board

March 28, 2023

Half Yearly Report and Accounts

February 28, 2023

Appendix 4C - Quarterly

January 30, 2023

Remplir Gains Australian Reimbursement

October 31, 2022

OrthoATI Rotator Cuff Study Success With Cross-Over Patients

September 28, 2022

First orders for Striate and Remplir

September 26, 2022

Appointment of Exclusive Australian Distributor for Remplir

September 7, 2022

Final Report and Annual Report to Shareholders

August 30, 2022

Striate Global License and Distribution Agreement Update

July 20, 2022

OCC Signs Striate Global License And Manufacturing Agreement

June 27, 2022

Final Data Readout for Orthocells Nerve Reconstruction Study

June 6, 2022

← Newer news releases · Older news releases →

Decks

The 5 newest of 35 decks. Every deck is listed under its year.